Amplification and overexpression of PRMT5 in breast cancer is associated with reduced patient survival rates (Figures S1D and S1E) (Cerami et al., 2012, Gao et al., 2013, Györffy et al., 2010). Here, PRMT5 is linked to breast cancer.